<DOC>
	<DOCNO>NCT00532623</DOCNO>
	<brief_summary>To evaluate overall response rate gemcitabine vinorelbine combination ( GV ) gemcitabine follow vinorelbine ( Gâ‡’V ) use palliative therapy patient stage IV recurrent breast cancer .</brief_summary>
	<brief_title>Phase II Study Gemcitabine/Vinorelbine v Sequential Gemcitabine Followed Vinorelbine Metastatic Breast Cancer</brief_title>
	<detailed_description>This open-label , randomize , two-arm , parallel group phase II study . Eligible patient randomize two treatment regimen , one gemcitabine vinorelbine combination therapy ( Group A ) gemcitabine monotherapy follow vinorelbine monotherapy ( Group B ) . Patients In group A monotherapy receive gemcitabine vinorelbine combination , patient group B receive gemcitabine monotherapy evidence disease progression follow vinorelbine . A total 82 patient enrol study . Patients randomize stratified accord number prior chemotherapy include adjuvant chemotherapy visceral disease . No maximum number cycle pre-determined . Patients may continue study therapy document treatment failure . Patients group A discontinue study therapy proceed post-therapy follow-up phase study . Patients group B discontinue study therapy treat gemcitabine proceed receive vinorelbine disease progression . Patients vinorelbine discontinue study therapy proceed post-therapy follow-up phase study . Further treatment upon discontinuation study therapy discretion investigator . A two arm , open label phase II study without control appropriate explore efficacy gemcitabine concurrent sequential vinorelbine patient population evaluate characterize toxicity two treatment approach , qualitatively quantitatively . The purpose randomization phase II study diminish possible impact selection bias treatment outcome thus interpretation efficacy safety data .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologic cytologic diagnosis stage IV recurrent breast cancer . Previous anthracycline and/or taxane and/or capecitabine chemotherapy adjuvant metastatic setting . Previous hormonal therapy adjuvant metastatic setting . Prior radiation therapy allow long irradiated area source measurable disease . No forms cancer therapy , radiation , immunotherapy least 3 week enrollment study . Performance status 0 , 1 , 2 ECOG criterion . Clinically measurable disease , define unidimensionally measurable lesion clearly define margin xray , CT scan , MRI physical examination . Lesions serve measurable disease must least 1cm 1cm , define xray , CT scan , MRI , physical examination . Estimated life expectancy least 12 week . Patient compliance allow adequate followup . Adequate hematologic ( WBC count3,000/mm3 , platelet count100,000/mm3 ) , hepatic ( bilirubin level1.5 mg/dL , AST , ALT3xULN ) , renal ( creatinine concentration 1.5 mg/dL ) function . Informed consent patient patient 's relative . Females least 18 year age . Childbearing woman use nonhormonal contraceptive method . Previous chemotherapy &gt; 3 recurrent stage IV disease Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin prior malignancy treat 5 year ago without recurrence ) . Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin prior malignancy treat 5 year ago without recurrence ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>